Yeast-derived L-asparaginase seen to be less toxic than an enzyme derived from bacteria.
Hematology
Latest News
Advertisement
CME Content
Advertisement
Top news of the week in oncology and cancer drug development.
Poor long-term survival rates for pediatric patients with acute megakaryoblastic leukemia.
Top news of the week in oncology and cancer drug development.
Top news of the week in oncology and cancer drug development.
Top news of the week in oncology and cancer drug development.
Combination therapy to be assessed in multiple myeloma and solid cancers.
Opdivo plus Darzalex will be investigated in a new clinical trial.
Top news of the week in oncology and cancer drug development.
Multiple clinical trials of vadastuximab talirine have been placed on clinical hold by the FDA.
ASN003 demonstrated potent action against tumor growth.
Hispanic newborns that develop acute lymphoblastic leukemia are 5.9% times more likely to have a cytomegalovirus infection at birth.
Cancer accounts for more years of life lost than any other cause of death.
Association between cancer diagnosis and suicide on a population level suggested.
Relapsed or refractory leukemia patients who received CC-486 had a 38% overall response rate.
Myeloproliferative neoplasms may negatively affect the physical and mental health of patients.
Thioguanine and decitabine combination therapy show positive results in phase 1 trial.
Patients share their personal stories with Specialty Pharmacy Times.
Top news of the week in oncology and cancer drug development.
Regular use of over-the-counter, anti-inflammatory drugs associated with an increased risk of death in patients with cancer.
Investigative drug may improve overall survival and reduce chemotherapy-induced heart damage in children with acute myelogenous leukemia.
Genetically engineered T cells show efficacy preventing acute myeloid leukemia relapse.
Novel immunotherapy shows promise treating patients with leukemia at high-risk of relapse.
Top news of the week in oncology and cancer drug development.
Rates of suicide elevated in cancer survivors diagnosed before the age of 25 years.
Advertisement
Advertisement
Trending on Pharmacy Times
1
ADCs in Breast Cancer: Shaping the Future of HER2– and TROP2-Targeted Therapy
2
Study: Many Patients Switching Biologics Because of Perceived Lack of Efficacy Treating Asthma
3
FDA Approves Targeted Combination Therapy for BRCA2-Mutated Prostate Cancer
4
Targeted ADCs Break Through Barriers in HER2-Positive Breast Cancer
5
